New York, states reach $700 mln settlement with Reckitt over opioid probes

Reckitt Benckiser will pay $700 million to New York and five other states as part of an agreed settlement over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday.

Adds details about the settlement

Oct 23 (Reuters) - Reckitt Benckiser RB.L will pay $700 million to New York and five other states as part of an agreed settlement over allegations that the drug distributor improperly marketed a drug to treat opioid addiction, New York Attorney General Letitia James said on Wednesday.

The payment is a part of an up to $1.4 billion settlement agreed to in July to resolve U.S. claims that Reckitt Benckiser's former pharmaceuticals business Indivior before it was spun out carried out an illegal scheme to boost sales of opioid addiction treatment Suboxone.

The $700 million settlement amount consists of $500 million to the federal government and up to $200 million to states that opt to participate in the agreement.

Indivior in April was indicted and accused of deceiving doctors and healthcare benefit programs into believing Suboxone Film, itself a form of opioid, was safer and less susceptible to abuse than similar drugs.

As part of the agreement, New York's Medicaid program will receive more than $71.9 million in recoveries, with more than $39.9 million being returned to New York State, James said. (https://on.ny.gov/31I36N4)

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Shailesh Kuber and Subhranshu Sahu)

((manojna.kalyani@thomsonreuters.com; within the U.S. +1 646 223 8780, outside the U.S. +91 80 6749 1692;))

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More